Abstract
The 5-year mortality rate for heart failure borders on 50%. The main cause is an ischaemic cardiac event where blood supply to the tissue is lost and cell death occurs. Over time, this damage spreads and the heart is no longer able to pump efficiently. Increasing vascularisation of the affected area has been shown to reduce patient symptoms. The growth factors required to do this have short half-lives making development of an efficacious therapy difficult. Herein, the angiogenic growth factor Vascular Endothelial Growth Factor (VEGF) is complexed electrostatically with star-shaped or linear polyglutamic acid (PGA) polypeptides. Optimised PGA-VEGF nanomedicines provide VEGF encapsulation of > 99% and facilitate sustained release of VEGF for up to 28 days in vitro. The star-PGA-VEGF nanomedicines are loaded into a percutaneous delivery compliant hyaluronic acid hydrogel. Sustained release of VEGF from the composite nano-in-gel system is evident for up to 35 days and the released VEGF has comparable bioactivity to free, fresh VEGF when tested on both Matrigel® and scratch assays. The final star-PGA-VEGF nanomedicine-loaded hydrogel is biocompatible and provides sustained release of bioactive VEGF. Therefore, we report the development of novel, self-assembling PGA-VEGF nanomedicines and their incorporation into a hyaluronic acid hydrogel that is compatible with medical devices to enable minimally invasive delivery to the heart. The final star-PGA-VEGF nanomedicine-loaded hydrogel is biocompatible and provides sustained release of bioactive VEGF. This formulation provides the basis for optimal spatiotemporal delivery of an angiogenic growth factor to the ischaemic myocardium.
Similar content being viewed by others
References
Pittman RN. The circulatory system and oxygen transport. In: Regulation of tissue oxygenation. Morgan & Claypool Life Sciences: San Rafael; 2011.
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Blood vessels and endothelial cells. In: Molecular biology of the cell. 4th ed. New York: Garland Science; 2002.
Buja LM, Vander Heide RS. Pathobiology of ischemic heart disease: past, present and future. Cardiovasc Pathol. 2016 May;25(3):214–20.
O’Brien FJ. Biomaterials & scaffolds for tissue engineering. Mater Today. 2011;14(3):88–95.
Duffy GP, McFadden TM, Byrne EM, Gill S-L, Farrell E, O’Brien FJ. Towards in vitro vascularisation of collagen-GAG scaffolds. Eur Cell Mater. 2011;21:15–30.
Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378(9792):704–12.
Cochain C, Channon KM, Silvestre J-S. Angiogenesis in the infarcted myocardium. Antioxid Redox Signal. 2013;18(9):1100–13.
Adair TH, Montani J-P. Angiogenesis. Morgan & Claypool Life Sciences; 2010.
Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851–8.
Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996;271(2):603–6.
Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J. 2001;142(5):872–80.
Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107(10):1359–65.
Silva EA, Mooney DJ. Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials. 2010;31(6):1235–41.
Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329–47.
Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm. 2002;233(1–2):51–9.
Golub J, Kim Y, Duvall C, Bellamakonda R, Gupta D, Lin A, et al. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am J Physiol Heart Circ Physiol. 2010;298(6):H1959–65.
Xie J, Wang H, Wang Y, Ren F, Yi W, Zhao K, et al. Induction of angiogenesis by controlled delivery of vascular endothelial growth factor using nanoparticles. Cardiovasc Ther. 2013;31(3):e12–8.
des Rieux A, Ucakar B, Mupendwa BPK, Colau D, Feron O, Carmeliet P, et al. 3D systems delivering VEGF to promote angiogenesis for tissue engineering. J Control Release. 2011;150(3):272–8.
Gu F, Amsden B, Neufeld R. Sustained delivery of vascular endothelial growth factor with alginate beads. J Control Release. 2004;96(3):463–72.
Oduk Y, Zhu W, Kannappan R, Zhao M, Borovjagin AV, Oparil S, et al. VEGF nanoparticles repair the heart after myocardial infarction. Am J Physiol Circ Physiol. 2018;314(2):H278–84.
Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282–95.
Yan Y, Wei D, Li J, Zheng J, Shi G, Luo W, et al. A poly(l-lysine)-based hydrophilic star block co-polymer as a protein nanocarrier with facile encapsulation and pH-responsive release. Acta Biomater. 2012;8(6):2113–20.
Byrne M, Thornton PD, Cryan S-A, Heise A. Star polypeptides by NCA polymerisation from dendritic initiators: synthesis and enzyme controlled payload release. Polym Chem. 2012;3(10):2825.
Wang X, Wu X, Xing H, Zhang G, Shi Q, E L, et al. Porous nanohydroxyapatite/collagen scaffolds loading insulin PLGA particles for restoration of critical size bone defect. ACS Appl Mater Interfaces. 2017;9(13):11380–91.
Saludas L, Pascual-Gil S, Prósper F, Garbayo E, Blanco-Prieto M. Hydrogel based approaches for cardiac tissue engineering. Int J Pharm. 2017;523(2):454–75.
Van Vlierberghe S, Dubruel P, Schacht E. Biopolymer-based hydrogels as scaffolds for tissue engineering applications: a review. Biomacromolecules. 2011;12(5):1387–408.
Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater. 2011;23(12):H41–56.
Dolan EB, Kovarova L, O’Neill H, Pravda M, Sulakova R, Scigalkova I, et al. Advanced Material Cath eter (AMCath), a minimally invasive endocardial catheter for the delivery of fast-gelling covalently cross-linked hyaluronic acid hydrogels. J Biomater Appl. 2018;33(5):681–92.
Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: enhanced loading efficiency and its pharmacokinetic evaluation. Int J Pharm. 2018;536(1):95–107.
Shen S, Wu Y, Liu Y, Wu D. High drug-loading nanomedicines: progress, current status, and prospects. Int J Nanomedicine. 2017;12:4085–109.
Tahergorabi Z, Khazaei M. A review on angiogenesis and its assays. Iran J Basic Med Sci. 2012;15(6):1110–26.
Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem. 2003;49(1):32–40.
Arnaoutova I, Kleinman HK. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc. 2010;5(4):628–35.
Quinlan E, López-Noriega A, Thompson EM, Hibbitts A, Cryan SA, O’Brien FJ. Controlled release of vascular endothelial growth factor from spray-dried alginate microparticles in collagen-hydroxyapatite scaffolds for promoting vascularization and bone repair. J Tissue Eng Regen Med. 2017;11(4):1097–109.
Duro-Castano A, England RM, Razola D, Romero E, Oteo-Vives M, Morcillo MA, et al. Well-defined star-shaped polyglutamates with improved pharmacokinetic profiles as excellent candidates for biomedical applications. Mol Pharm. 2015;12(10):3639–49.
Anderson W, Kozak D, Coleman VA, Jämting ÅK, Trau M. A comparative study of submicron particle sizing platforms: accuracy, precision and resolution analysis of polydisperse particle size distributions. J Colloid Interface Sci. 2013;405:322–30.
Filipe V, Hawe A, Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res. 2010;27(5):796–810.
Byrne M, Victory D, Hibbitts A, Lanigan M, Heise A, Cryan S-A. Molecular weight and architectural dependence of well-defined star-shaped poly(lysine) as a gene delivery vector. Biomater Sci. 2013;1(12):1223.
Kita K, Dittrich C. Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug–carrier interactions. Expert Opin Drug Deliv. 2011;8(3):329–42.
Rui J, Dadsetan M, Runge MB, Spinner RJ, Yaszemski MJ, Windebank AJ, et al. Controlled release of vascular endothelial growth factor using poly-lactic-co-glycolic acid microspheres: in vitro characterization and application in polycaprolactone fumarate nerve conduits. Acta Biomater. 2012;8(2):511–8.
Mortensen A, Aguilar F, Crebelli R, Di Domenico A, Dusemund B, Frutos MJ, et al. Re-evaluation of glutamic acid (E 620), sodium glutamate (E 621), potassium glutamate (E 622), calcium glutamate (E 623), ammonium glutamate (E 624) and magnesium glutamate (E 625) as food additives. EFSA J. 2017;15(7).
Kleinheinz J, Jung S, Wermker K, Fischer C, Joos U. Release kinetics of VEGF165 from a collagen matrix and structural matrix changes in a circulation model. Head Face Med. 2010;6:17.
Staton CA, Reed MWR, Brown NJ. A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol. 2009;90(3):195–221.
Liang C-C, Park AY, Guan J-L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2(2):329–33.
Anderson SM, Siegman SN, Segura T. The effect of vascular endothelial growth factor (VEGF) presentation within fibrin matrices on endothelial cell branching. Biomaterials. 2011;32(30):7432–43.
Mann DL, Lee RJ, Coats AJS, Neagoe G, Dragomir D, Pusineri E, et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur J Heart Fail. 2016;18(3):314–25.
Acknowledgements
The authors acknowledge the support of Brenton Cavanagh for assistance with imaging and Matrigel® analysis.
Funding
Financial support for this project was provided by Science Foundation Ireland (SFI) under an Investigator Award grant number 13/IA/1840 and the AMCARE consortium, a European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement number 604531.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(PDF 553 kb)
Rights and permissions
About this article
Cite this article
O’Dwyer, J., Murphy, R., Dolan, E.B. et al. Development of a nanomedicine-loaded hydrogel for sustained delivery of an angiogenic growth factor to the ischaemic myocardium. Drug Deliv. and Transl. Res. 10, 440–454 (2020). https://doi.org/10.1007/s13346-019-00684-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13346-019-00684-5